Loading…
iSpecimen Inc. is projected to decline to $1.91 by 2027, a -5% move from its current price of $2.01. ISPC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.93 | $2.01 | $2.10 | +0.09% |
| Aug 6 | $1.89 | $2.01 | $2.14 | +0.17% |
| Aug 7 | $1.87 | $2.02 | $2.17 | +0.26% |
| Aug 8 | $1.85 | $2.02 | $2.20 | +0.35% |
| Aug 9 | $1.83 | $2.02 | $2.22 | +0.44% |
| Aug 10 | $1.82 | $2.02 | $2.25 | +0.53% |
| Aug 11 | $1.80 | $2.02 | $2.27 | +0.61% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.80 | $2.02 | $2.27 | +0.61% |
| Week 2 | $1.73 | $2.03 | $2.39 | +1.23% |
| Week 3 | $1.68 | $2.05 | $2.50 | +1.85% |
| Week 4 | $1.64 | $2.06 | $2.59 | +2.48% |
| Week 5 | $1.60 | $2.07 | $2.68 | +3.11% |
| Week 6 | $1.58 | $2.09 | $2.76 | +3.74% |
| Week 7 | $1.55 | $2.10 | $2.84 | +4.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.
The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types.
It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
ISPC trades at $1.83, reflecting a small-cap profile with a relatively modest market footprint.
The stock carries a market capitalization of $2.63M and is ranked 5123 by market cap size.
The price outlook from the accompanying year-by-year forecast shows subtle near-term activity alongside meaningful longer-run upside, with the average price rising in several later years (for example, 2029 avg $2.50 and 2030 avg $2.49) and a far-reaching apex by 2050 at avg $6.46.
Overall, the numbers indicate a volatile but potentially higher-lying long-run path, with multiple years labeled bullish and a wide max-price trajectory out to 2050.
A major floor 39.8% below — a decisive break under it would weaken the trend.
The nearest floor, 9.0% below — buyers have tended to step in here.
The nearest ceiling, 38.8% above — a clean break opens room to run.
A major ceiling 222.4% above — clearing it would confirm fresh momentum.
Key ISPC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ISPC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.90 | Buy | $1.92 | Buy |
| MA 10 | $2.05 | Sell | $2.02 | Sell |
| MA 20 | $2.21 | Sell | $2.19 | Sell |
| MA 50 | $2.64 | Sell | $2.95 | Sell |
| MA 100 | $4.30 | Sell | $5.55 | Sell |
| MA 200 | $11.20 | Sell | $16.83 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.31 | Neutral |
| Stoch RSI (14) | 29.48 | Neutral |
| CCI (20) | -113.75 | Sell |
| Williams %R (14) | -89.29 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -15.25 | Sell |
| Bollinger %B (20,2) | 0.14 | Neutral |
| Stochastic %K (14) | 10.71 | Buy |
| TRIX (15) | -1.27 | Sell |
| Awesome (5,34) | -0.49 | Sell |
| Ultimate (7,14,28) | 25.35 | Buy |
| Momentum (10) | -0.21 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 1.79 | Buy |
| ADX (14) | 30.19 | Sell |
| ATR (14) | 0.10 | Info |
The near-term technical picture is bearish, with RSI at 30.
The 50-day simple moving average (SMA50) is $2.67, well below the 200-day simple moving average (SMA200) of $11.36, which suggests downward momentum in the short term.
Current price sits at the $1.83 support level, with resistance at $2.79. The stock has traded a 30-day range from a low of $1.37 to a high of $2.44, and annualized volatility stands at 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.83 | $2.01 | $2.63 | 0% | Neutral | |
| $1.44 | $1.91 | $2.71 | -5% | Neutral | |
| $1.47 | $2.04 | $3.07 | +2% | Neutral | |
| $1.88 | $2.71 | $4.25 | +35% | Bullish | |
| $1.82 | $2.73 | $4.44 | +36% | Bullish | |
| $1.62 | $2.51 | $4.20 | +25% | Bullish | |
| $1.51 | $2.41 | $4.14 | +20% | Neutral | |
| $1.42 | $2.34 | $4.13 | +17% | Neutral | |
| $1.51 | $2.56 | $4.61 | +27% | Bullish | |
| $1.69 | $2.94 | $5.39 | +46% | Bullish | |
| $1.57 | $3.11 | $6.22 | +55% | Bullish | |
| $3.18 | $7.06 | $15.87 | +251% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.83 | $2.01 | $2.43 | +0.00% |
| September 2026 | $1.76 | $2.11 | $2.64 | +5.20% |
| October 2026 | $1.79 | $2.18 | $2.76 | +2.94% |
| November 2026 | $1.69 | $2.07 | $2.66 | -5.01% |
| December 2026 | $1.63 | $2.02 | $2.63 | -2.26% |
Click any year to see its month-by-month ISPC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ISPC price prediction for 2026 points to an average of $2.01 (low $1.83, high $2.63) — a potential gain of 0% on today's $2.01. Price action looks broadly range-bound.
In 2027, ISPC is projected to trade between $1.44 and $2.71, averaging $1.91 — a potential decline of -5% from today's $2.01. That is -5% versus the projected 2026 average. A consolidation phase looks the most probable path here.
iSpecimen Inc.'s 2028 outlook centres on $2.04, within a $1.47 to $3.07 range. That is up +7% on the projected 2027 average. That marks a +2% change versus current levels. Price action looks broadly range-bound.
By 2029, ISPC could reach as high as $4.25, with a base case around $2.71 and support toward $1.88 — roughly +35% from $2.01. Buyers look set to stay in control over this stretch.
Expect ISPC to range from $1.82 to $4.44 through 2030. The $2.73 average target implies a +36% move from current prices. That is up +1% on the projected 2029 average. Momentum favours further upside here.
The ISPC price prediction for 2031 points to an average of $2.51 (low $1.62, high $4.20) — a potential gain of +25% on today's $2.01. Buyers look set to stay in control over this stretch.
In 2032, ISPC is projected to trade between $1.51 and $4.14, averaging $2.41 — a potential gain of +20% from today's $2.01. That is -4% versus the projected 2031 average. Price action looks broadly range-bound.
iSpecimen Inc.'s 2033 outlook centres on $2.34, within a $1.42 to $4.13 range. That is -3% versus the projected 2032 average. That marks a +17% change versus current levels. A consolidation phase looks the most probable path here.
By 2034, ISPC could reach as high as $4.61, with a base case around $2.56 and support toward $1.51 — roughly +27% from $2.01. Momentum favours further upside here.
Expect ISPC to range from $1.69 to $5.39 through 2035. The $2.94 average target implies a +46% move from current prices. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ISPC price prediction for 2040 points to an average of $3.11 (low $1.57, high $6.22) — a potential gain of +55% on today's $2.01. Momentum favours further upside here.
In 2050, ISPC is projected to trade between $3.18 and $15.87, averaging $7.06 — a potential gain of +251% from today's $2.01. That is up +127% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ISPC today (≈ 497.512438 ISPC) could be worth
$3,510.96
+$2,510.96 (+251%) by 2050 · US Dollar
Based on the average projected ISPC price of $7.06 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ISPCwould be worth at today's price.
$1,000 invested in ISPC on Jul 31, 2025 (≈ 20.161291 ISPC) would be worth
$40.52
-$959.48 (-95.9%) today · 0.04× · US Dollar
Based on a ISPC entry price of $49.6 vs. today's $2.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.97 | $1,020.3 | +2.0% |
| 1 month ago | $2.73 | $736.26 | -26.4% |
| 3 months ago | $5.62 | $357.65 | -64.2% |
| 6 months ago | $13.64 | $147.36 | -85.3% |
| 1 year ago | $49.6 | $40.52 | -95.9% |
| All time (5.0y) ago | $4,688 | $0.43 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ISPC forecast.
Our base-case forecast reaches $4.00 around 2050.
Implied market cap at $4.00: $5.75M
The multi-year forecast shows a sequence of years with mixed sentiment, transitioning to bullish momentum in several later years. The 2026 forecast sits at an average of $1.83 with 0% ROI and neutral sentiment, followed by 2027 at an average of $1.73 with a -5.2% ROI and neutral sentiment, and 2028 at an average of $1.85 with a 1.2% ROI and neutral sentiment.
In 2029 the average moves to $2.50 with a 36.4% ROI and bullish sentiment, and 2030 to $2.49 with a 36.2% ROI and bullish sentiment. The trajectory remains bullish through 2031 ($2.26 avg, 23.7% ROI), 2032 ($2.21 avg, 21% ROI), and 2034 ($2.31 avg, 26.4% ROI). 2035 shows a strong increase to $2.70 avg with a 47.5% ROI, followed by 2040 at $2.83 avg and 54.4% ROI.
The far horizon projects continued upside, with 2050 posting an average of $6.46 and a sizable 253.1% ROI, under bullish sentiment. These are estimates and not guarantees; actual results may vary. Risk remains inherent in projecting small-cap, illiquid assets over long horizons.
Tap a question to reveal the answer.
In 2030, the forecast shows min $1.66, avg $2.49, max $4.06 with a 36.2% ROI and bullish sentiment.
The forecast includes years labeled bullish (e.g., 2029, 2030, 2031, 2032, 2034, 2035, 2040, 2050) with meaningful average price increases and double-digit ROIs, but there are neutral or negative periods such as 2026 (0% ROI) and 2027 (-5.2% ROI). This indicates mixed prospects and no guaranteed outcome.
Yes. The 2040 forecast max is $5.67, and the 2039-2040 window includes values that exceed $5, with a 2040 max of $5.67 and 2050 max of $14.61.
Current price is $1.83 and market capitalization is $2.63M.
The near-term outlook is bearish with RSI 14 at 30. The SMA50 is $2.67, SMA200 is $11.36, price support sits at $1.83 and resistance at $2.79. The 30-day range spans $1.37 to $2.44, and volatility is 80%.
iSpecimen Inc. Community Discussion
0Share your iSpecimen Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.